Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.

A modern collection of imaging innovations offers a new path to healthcare and medical research, framing a new era of medical diagnostic solutions

Feature | Magnetic Resonance Imaging (MRI) | By Robert L. Bard, MD, and Lennard M. Gettz, EdD

The Full Body Imaging Movement: A Strategic Upgrade of the MRI

Since the advent of the magnetic resonance imaging (MRI) exam on human patients in the late 1970s, this innovation ...

September 25, 2023

Scientists in Moscow have successfully engineered a prototype detector for X-ray and PET/CT mаchines, using the perovskite-based photoconverters

News | X-Ray

Moscow Scientists Initiate Groundbreaking Testing of X-ray Machine Detectors

September 21, 2023 — Scientists in Moscow have successfully engineered a prototype detector for X-ray and PET/CT ...

September 21, 2023

Advancements in research, technology and partnerships are combining to enhance availability and access

Feature | Proton Therapy | By Christine Book

Targeting Cancer, Tracking Collaboration: A Progress Report on Proton Therapy

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

September 21, 2023

Sponsored Content

Staging F-18 FDG PET/CT images of adenocarcinoma in the RUL of the lung illustrates the value of Vereos. The primary lesion in the right upper lobe appears in the upper row (PET image is left, CT image is right). A 3 mm synchronous primary or metastatic lesion in the RUL is apparent in the lower row. The precision afforded by Vereos' images provided the basis for the patient to undergo RUL lobectomy instead of thermal ablation of the primary lesion. Images courtesy of Dr. Jay Kikut and UVM

Blog | PET-CT

Digital PET Balances Scan Time and Resolution

Efficiency and effectiveness are inseparable in clinical medicine. Digital PET addresses them both. The key is the ...

October 25, 2018

This molecule may significantly expand the patient population eligible for SCINTIX therapy to patients with solid tumor cancers of any stage in a manner that may improve both outcomes and procedural workflow

News | Radiation Therapy

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

September 20, 2023

A the COVID-19 public health emergency continues to evolve, SNMMI issues updated guidance

News | SNMMI

SNMMI Issues Updated Statement: COVID-19 and V/Q Lung Studies

September 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), as a professional society ...

September 18, 2023

The clinical study of Positron’s Affinity PET-CT is designed to provide key information that evaluate the new system and its full capabilities with multiple radiopharmaceuticals and new coronary flow software applications that will enhance physician’s diagnostic analysis

News | PET-CT

Positron Corporation Announces Start of Clinical Study of Affinity PET-CT Device

September 8, 2023 — Positron Corporation, a leading molecular imaging medical device company, is pleased to announce ...

September 08, 2023

The AURA 10 is now poised to help enhance surgical outcomes in the United States

News | PET-CT

XEOS Receives Approval by US FDA for the AURA 10 PET-CT Specimen Imager for the Operating Room

September 7, 2023 — The groundbreaking AURA 10 specimen imager by Belgian MedTech pioneer XEOS has been cleared by the ...

September 07, 2023

Feature | PET Imaging

PET Radiotracer Market anticipated to reach $3.2 Billion in Revenues by 2031

According to a new report from Transparency Market Research (TMR), PET radiotracers are expected to rise at a CAGR of 8 ...

September 05, 2023

NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Curadh’s molecularly targeted radiation (MTR) programs for treatment of solid tumors

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

August 31, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

August 31, 2023

First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity

News | Radiopharmaceuticals and Tracers

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

August 29, 2023 — NorthStar Medical Radioisotopes, LLC (“NorthStar"), a global innovator in the development, production ...

August 29, 2023

News | Radiopharmaceuticals and Tracers

Carolina Breast Imaging Specialists, PLLC Is First in Nation to Adopt Groundbreaking Imagio Breast Imaging System for Breast Cancer Diagnosis

August 29, 2023 — Mammograms are an essential part of preventive healthcare, and when an initial review reveals a ...

August 29, 2023

Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer

News | Radiopharmaceuticals and Tracers

PanTera and TerraPower Isotopes Join Forces to Accelerate Access to Actinium-225

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that ...

August 28, 2023

New UBC Okanagan research takes aim at improving diagnostic imaging

News | Radiology Imaging

Riding a Wave to Better Medical Diagnosis

August 24, 2023 — Medical imaging via X-rays, CT scans, MRIs and ultrasounds provide health-care professionals with ...

August 24, 2023

Radiopharmaceutical-directed treatment ushers in a new era of autonomous radiotherapy

News | Radiation Therapy

World’s First Cancer Patient Treated with RefleXion’s Breakthrough SCINTIX Biology-guided Radiotherapy

August 23, 2023 — RefleXion Medical, a therapeutic oncology company, today announced that the first patient has ...

August 23, 2023

Study investigated impact of radiographic media contrast shortage on stroke patient scan data

News | Contrast Media

Researchers Discover Contrast Dye Shortage Affected Assessment of Stroke Patients

August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...

August 17, 2023

In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy

News | Prostate Cancer

PSMA PET/CT Waives the Need for Pre-imaging Biopsy in Elderly Patients

August 15, 2023 — In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid ...

August 15, 2023

FDA-approved generic for MRI procedures is fully substitutable for Gadavist

News | Contrast Media

Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection

August 8, 2023 — Fresenius Kabi announced it has launched Gadobutrol Injection, a generic substitute for the contrast ...

August 08, 2023

News | Radiation Therapy

RayCare in Clinical Use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

August 3, 2023 —RaySearch Laboratories AB announced that Lausanne University Hospital (CHUV), Switzerland, has treated ...

August 03, 2023

Now radiology departments, imaging technologists and medical experts have a solution they can use to help tackle these challenges.

Sponsored Content | Case Study | Enterprise Imaging

Redefining Radiology

The healthcare industry faces many different types of obstacles in today’s challenging marketplace. Staff shortages ...

August 01, 2023

FDA-approved in May 2023, POSLUMA is commercially available through 36 radiopharmacies across the United States

News | Prostate Cancer

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

July 28, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

July 28, 2023